Article
Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.
Clinical and translational medicine - 1 May 2021
Zhang Wenxin, Wang Ruixia, Fang Huan, Ma Xiangyuan, Li Dan, Liu Tao, Chen Zhenxi, Wang Ke, Hao Shiguang, Yu Zicheng, Chang Zhili, Na Chenglong, Wang Yin, Bai Jian, Zhang Yanyan, Chen Fang, Li Miao, Chen Chao, Wei Liangshen, Li Jinghua, Chang Xiaoyan, Qu Shoufang, Yang Ling, Huang Jie
Abstract excerpt
BACKGROUND: Tumor mutational burden (TMB) is a promising biomarker for stratifying patient subpopulation who would benefit from immune checkpoint blockade (ICB) therapies. Although great efforts have been made for standardizing TMB measurement, mutation calling and TMB quantification can be challenging in samples with low tumor content including liquid biopsies. The effect of varying tumor content on TMB...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.